Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments
- Conditions
- VestibulodyniaTemporomandibular DisorderMigrainesTension HeadacheFibromyalgia SyndromeInterstitial CystitisChronic Fatigue SyndromeBack PainIrritable Bowel SyndromeEndometriosis
- Interventions
- Drug: Placebo pillDrug: Placebo cream
- Registration Number
- NCT03844412
- Lead Sponsor
- Duke University
- Brief Summary
Vestibulodynia (VBD) is a complex chronic vulvar pain condition that impairs the psychological, physical, and sexual health of 1 in 6 reproductive aged women in the United States. Here, the investigators plan to conduct a randomized, double-blinded, placebo-controlled clinical trial to 1) compare the efficacy of peripheral (lidocaine/estradiol cream), centrally-targeted (nortriptyline), and combined treatments in alleviating pain and improving patient-reported outcomes and 2) determine cytokine and microRNA biomarkers that predict treatment response in women with distinct VBD subtypes. Positive findings from this study will readily translate to improved patient care, permitting the millions of women with VBD, their partners, and their clinicians to make more informed decisions about pain management.
- Detailed Description
Vestibulodynia (VBD) is a chronic pelvic pain condition that affects 1 in 6 reproductive aged women, yet remains ineffectively treated by standard trial-and-error approaches. The investigators have identified two distinct VBD subtypes that may benefit from different types of treatment: 1) VBD peripheral (VBD-p) subtype characterized by localized pain specific to the vulvar vestibule, and 2) VBD central (VBD-c) subtype characterized by pain at both vaginal and remote body regions. Preliminary data further demonstrate that VBD-p and VBD-c subtypes differ with respect to patient reported outcomes (e.g., physical and mental health), production of cytokines (intracellular proteins that regulate the activity of pain nerves and inflammatory processes), and expression of microRNAs (small non-coding RNA molecules that regulate gene expression). Women with VBD-p exhibit normal psychological profiles; balanced circulating pro- and anti-inflammatory cytokines; and dysregulation in microRNAs that regulate the expression of genes in estrogen pathways. In contrast, women with VBD-c report decreased functional status and increased somatization; increased pro-inflammatory but not anti-inflammatory cytokines; and dysregulation in microRNAs that regulate the expression of genes relevant to muscle, nerve, and immune cell function. Based on these data, the investigators hypothesize that two VBD-p and VBD-c subtypes will preferentially respond to peripheral, central, or combined treatments and can be distinguished by cytokine and microRNA profiles. These hypotheses will be tested in a phase III clinical trial that evaluates diverse treatment strategies in women with VBD-p and VBD-c. Participants will be randomly assigned to one of four parallel arms: peripheral treatment with 5% lidocaine + 0.5 mg/ml 0.02% estradiol compound cream, 2) central treatment with the tricyclic antidepressant nortriptyline, 3) combined peripheral and central treatments, or 4) placebo. The treatment phase will last 4 months (with a 6-week titration at treatment initiation and 2-week taper period at 4 months), with outcome measures and biomarkers assessed at 4 time points (0, 2, 4, and 6 months). First, the investigators will compare the efficacy of treatments in alleviating pain among women with VBD-p and VBD-c using standardized tampon insertion with a numeric rating scale and self-reported pain on the McGill Pain Questionnaire. Next, the investigators will compare the efficacy of treatments in improving perceived physical, mental, and sexual health among women with VBD-p and VBD-c using standardized questionnaires. Finally, investigators will measure cytokines and microRNAs in women with VBD-p versus VBD-c using multiplex assays and RNA sequencing, and determine the ability of these biomarkers to predict treatment response. Successful completion of the proposed work will provide new insights into the mechanisms that drive pain perception and treatment response in two distinct VBD subtypes, and determine the efficacy of peripheral, central, and combined therapies in reversing this pain. Such findings will readily translate to improved patient care, permitting the millions of women with VBD, their partners, and clinicians to make more informed decisions about pain management.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 223
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- FACTORIAL
- Arm && Interventions
Group Intervention Description placebo Placebo pill placebo cream and placebo pill peripheral treatment Placebo pill 5% lidocaine/5 mg/ml 0.02% estradiol compound cream central treatment Placebo cream tricyclic antidepressant nortriptyline pill combined peripheral and central treatments 5% lidocaine/5 mg/ml 0.02% estradiol compound cream 5% lidocaine/5 mg/ml 0.02% estradiol compound cream and tricyclic antidepressant nortriptyline pill placebo Placebo cream placebo cream and placebo pill peripheral treatment 5% lidocaine/5 mg/ml 0.02% estradiol compound cream 5% lidocaine/5 mg/ml 0.02% estradiol compound cream central treatment Nortriptyline tricyclic antidepressant nortriptyline pill combined peripheral and central treatments Nortriptyline 5% lidocaine/5 mg/ml 0.02% estradiol compound cream and tricyclic antidepressant nortriptyline pill
- Primary Outcome Measures
Name Time Method Change in self-reported pain via the Short Form- McGill Pain Questionnaire (SF-MPQ) Baseline, 16 weeks The SF-MPQ will be used to create a summary score. The SF-MPQ measures perceived sensory qualities of pain using 11 describers and affective qualities related to pain using 5 describers. Responses on 4-point scales are summed to compute scores for each section.
Change in pain score during the tampon test Baseline, 16 weeks The Tampon Test will provide a self-reported numeric rating scale of pain with self-tampon insertion, performed by the patient and reported to the research nurse. Participants will be asked to verbally rate the pain on a scale of 0-10, with 0 meaning no pain and 10 meaning the worst possible pain.
Change in self-reported physical/mental health via SF-12 Health Survey (SF12v2) Baseline, 16 weeks The SF-12 assesses 6 domains: global health, physical functioning, physical roles, emotional functioning, emotional roles and pain interference using an algorithm based on answers to 12 physical and mental health-related questions.
Change in sexual health via Patient-Reported Outcomes Measurement Information System (PROMIS) Baseline, 16 weeks The PROMIS score is based on a 96-item form developed by the NIH that measures 11 domains of biopsychosocial function and includes an assessment of sexual function measures (e.g., desire, frequency, fear, and pain) related to sexual intercourse.
Change in inflammation as measured by cytokine expression levels Baseline, 16 weeks Cytokine expression levels will be measured via mesoscale discovery assays.
Change in regulators of pro-pain and pro-inflammatory genes, as measured by microRNA expression levels Baseline, 16 weeks MicroRNA expression levels will be measured via sequencing read.
- Secondary Outcome Measures
Name Time Method Change in pain level as measured by Vaginal Vestibule Pressure Pain Intensities (PPI) Baseline, 8 weeks, 16 weeks, and 24 weeks Vaginal Vestibule PPIs will be determined using a cotton swab applied to 6 externally-accessed sites (at 12, 10, 7, 6, 5, 2 o'clock on the vestibule) for 1-2 seconds. Upon application of cotton swab at each site, participants will rate their pain intensity on a scale from 0-10.
Levator Muscle Complex Pressure Pain Thresholds (PPTs) Baseline, 8 weeks, 16 weeks, and 24 weeks Levator Muscle Complex PPTs will be determined using a digital vestibular algometer applied internally to the right, midline, and left puborectalis levator muscles sites (5, 6, and 7 o'clock) just lateral to the perineum.
Change in pain level as measured by Remote Bodily PPTs Baseline, 8 weeks, 16 weeks, and 24 weeks Remote Bodily PPTs will be determined by applying the algometer to 3 'neutral' non-pelvic body sites (deltoid, shin, and trapezius), right and left, beginning at 1N and increasing until the participant's first sensation of pain. A composite score will be calculated.
Change in degree of overlapping pain, as measured by COPC follow-up survey Baseline, 8 weeks, 16 weeks, and 24 weeks The COPC survey consists of 2 questions used to determine the change in degree of overlapping pain.
Change in mood as measured by the Symptom Checklist-27 (SCL-27) Baseline, 8 weeks, 16 weeks, and 24 weeks Symptom Check List 27 (SCL-27) questionnaire will be used to measure a broad range of psychological symptoms (e.g., anxiety and depression).
Change in somatic awareness via Pennebaker Index of Limbic Languidness (PILL) Baseline, 8 weeks, 16 weeks, and 24 weeks Pennebaker Index of Limbic Languidness (PILL) is used to create a summary score of somatic symptoms (e.g., itchy eyes, dizziness). Symptom frequency is recorded on a five-point Likert scale ranging from "never" to "more than once a week".
Change in perceived stress via Perceived Stress Scale (PSS) Baseline, 8 weeks, 16 weeks, and 24 weeks The Perceived stress scale (PSS) is a 10-item scale that measures the impact of personal stress on thoughts and feelings.
Change in sleep as measured by the sleep scale Baseline, 8 weeks, 16 weeks, and 24 weeks The sleep scale is a 12-item scale that measures amount of sleep and ease/difficulty of initiating and maintaining sleep.
Change in in pain score during the tampon test at other time points 8 weeks and 24 weeks Change in pain score during the tampon test will be measured as described above.
Change in cytokine biomarkers at other time points 8 weeks and 24 weeks Change in cytokine levels will be measured as described above.
Change in microRNA biomarkers at other time points 8 weeks and 24 weeks Change in microRNA levels will be measured as described above.
Change in self-reported health on the PROMIS at other time points 8 weeks and 24 weeks Change in self-reported outcomes on the PROMIS will be measured. The PROMIS score is based on a 96-item form developed by the NIH that measures 11 domains of biopsychosocial function and includes an assessment of sexual function measures (e.g., desire, frequency, fear, and pain) related to sexual intercourse.
Change in in pain score via the SF-MPQ at other time points 8 weeks and 24 weeks Change in pain score via the SF-MPQ will be measured as described above.
Change in self-reported health on the SF12v2 at other time points 8 weeks and 24 weeks Change in self-reported health on the SF12v2 will be measured as described above.
Trial Locations
- Locations (2)
University of North Carolina at Chapel Hill
🇺🇸Chapel Hill, North Carolina, United States
University of California, Los Angeles
🇺🇸Los Angeles, California, United States